Understand the source comparison
Comparison: Thymalin vs Other Thymus Support Research Peptides
Thymalin Thymic epithelial cell (TEC) activation via bioactive thymus-derived fragments Increases cortical TEC density 18–24% in aged models; restores thymus mass 22–35% Phase II trials show 34% CD3+ increase, 22% RTE elevation in geriatric cohorts Thymic invo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic epithelial cell (TEC) activation via bioactive thymus-derived fragments
- Increases cortical TEC density 18–24% in aged models; restores thymus mass 22–35%
- Phase II trials show 34% CD3+ increase, 22% RTE elevation in geriatric cohorts
- Thymic involution reversal, post-chemotherapy immune reconstitution studies
- Thymosin Alpha-1
- Enhances T-cell differentiation and maturation via cytokine modulation
- Indirect thymus support through IL-2 and IFN-gamma upregulation; no structural restoration data
- FDA-approved (orphan status) for hepatitis B/C; extensive safety profile
- Viral immunotherapy, cancer adjuvant, vaccine response enhancement
- Epithalon
- Telomerase activation and pineal gland function; secondary immune effects
- No direct thymus tissue studies; immune benefits inferred from longevity models
- Limited human trials (Russia); primarily preclinical aging research
- Lifespan extension research, circadian regulation studies
- TB-4 (Thymosin Beta-4)
- Tissue repair and angiogenesis; anti-inflammatory signaling
- Improves wound healing and cardiac repair; thymus effects not primary focus
- Phase II cardiac trials; veterinary use established
- Regenerative medicine, wound healing, ischemic injury models